Technical Accelerator Diligence: Future-Proofing a Digital Health Platform

A fast-growing digital health platform, launched by a seasoned health-tech entrepreneur post-exit to IQVIA, is pioneering real-world evidence (RWE) generation by enabling patients to share treatment experiences through structured surveys. While the platform held significant promise in transforming patient-reported outcomes into actionable insights for pharmaceutical clients, a private equity firm, considering investment, sought to review its enterprise-readiness.

To support this, our team at NextGen Invent conducted a structured Technical Accelerator Diligence (TAD) to evaluate, harden, and future-proof the platform across strategic, technological, and operational dimensions. The assessment spanned architecture, DevSecOps maturity, data privacy (aligned with ISO 27001:2022 and PIPEDA), AI-driven analytics, disaster recovery, and development readiness. Our findings included prioritized action items and a phased roadmap to strengthen security, scalability, and compliance while unlocking AI and data value.

Technology Used Technical Due Diligence, PostgreSQL, Grafana, Prometheus, AWS

The client is a digital health innovator offering a platform where patients share their treatment experiences through structured surveys. These insights, collected from validated users, are transformed into real-world evidence for pharmaceutical companies via a paid subscription. The solution combines BI dashboards, patient engagement modules, and co-pay program management to optimize adherence and improve patient outcomes.

360 Audit Readiness & Documentation
85% Reduction in Credential Exposure Risk

Industry

Healthcare

Business Problem

Private Equity Concerns Regarding Product Shortcomings

  • Lack of AI Monetization Strategy: The platform lacked a defined strategy to scale real-world evidence (RWE) capabilities or monetize data through AI/ML. No technical roadmap existed to drive advanced analytics, limiting long-term enterprise value creation through data science.
  • Disconnected Systems & No AI-Ready Pipeline: The absence of a data-matching framework between systems created fragmented datasets and blind spots. This disconnect reduced data quality, undermined insights accuracy, and hindered the development of pipelines essential for future AI/ML model deployment.
  • Static Credentials & Poor Modularity: The lack of audit logging and tight coupling between UI and logic led to reduced traceability, maintainability, and developer efficiency, blocking scalability and security.

Solution Approach

  • AI & Data Strategy Roadmap: We outlined a scalable roadmap to monetize patient-generated data and enhance RWE capabilities. The strategy includes creating AI-powered analytics features for pharmaceutical partners, driving deeper engagement, and enabling future Gen AI integrations aligned with business use cases.
  • Security Hardening: We implemented enhanced security protocols, including key management policies, audit trails, and compliance alignment with ISO 27001:2022 and PIPEDA. These controls closed critical gaps in access, risk, and change management, strengthening compliance posture and protecting enterprise value.
  • Tech Stack Optimization: We recommended standardizing the tech stack and modularizing the codebase to improve agility, reduce technical debt, and streamline development.
  • Automated Security Audits & VAPT: To mitigate hidden risks and data blind spots, we proposed SIEM tools and automated VAPT routines, enhancing threat detection and audit trails. This increases investor confidence, improves compliance posture, and accelerates readiness for AI/Gen AI deployment with fewer security risks.

Value Delivered

Through our Technical Accelerator Diligence service, we delivered a comprehensive blueprint to enhance the platform’s maturity across security, reliability, and compliance. This initiative empowered the client to proactively address regulatory gaps, streamline operational bottlenecks, and establish scalable processes for data governance and application lifecycle management.

Key risks, including untested disaster recovery procedures, hard coded secrets, and lack of audit evidence, surfaced and assigned resolution timelines. Additionally, by mapping the client’s goals to ISO 27001 and PIPEDA, we enabled enterprise-grade policy alignment to attract future pharma partners and scale globally with confidence.

The result is a future-ready digital health platform that not only strengthens its core architecture and compliance foundation but is also poised to evolve with AI, embedded analytics, and automated governance.

Our Case Study

Stay In the Know

Get Latest updates and industry insights every month